Shares of Clovis Oncology Inc. CLVS, -20.11% tanked more than 22% in the extended session Tuesday after the Boulder, Colo.,-based biopharma company reported a wider-than-expected third-quarter loss and quarterly sales missed expectations. Clovis said it lost $89.9 million, or $1.71 a share, in the quarter, compared with a loss of $61 million, or $1.24 a share, in the third quarter of 2017. Revenue rose to $23 million from $17 million a year ago. Analysts polled by FactSet had expected a loss of $1.59 a share on sales of $30 million for the quarter. Clovis shares ended the regular trading day down 0.5%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.